| |
JERSEY CITY, N.J., September 17, 2007
-- Lux
Biosciences, Inc.,
a privately held biotechnology company specialized in
the field of ophthalmic diseases,
announced today that Ulrich Grau, President and CEO, will
present a company overview at the 2007 UBS Global Life Sciences Conference
in New York. The presentation will take place at
2:00 pm ET
on Monday, September 24th, 2007.
The presentation will
be webcast live and may be accessed at
http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924.
An archived version of the webcast will be available at the same location
for 30 days following the presentation.
About Lux Biosciences
Lux Biosciences is a privately held biotechnology company
dedicated to the identification, optimization, development and
commercialization of products for the treatment of ophthalmic diseases.
The company's business strategy is characterized by:
-
A focus on compounds
already marketed or with clinical proof-of-concept in non-ophthalmic
indications that Lux Biosciences will develop as unique, targeted
therapies for corresponding ophthalmic diseases, with potentially
greater efficacy and safety than existing treatments.
-
A clinical-stage
portfolio of projects including: i) LX211, a
next-generation calcineurin
inhibitor that has potential in several ophthalmic diseases and, as
such, represents a pipeline of product opportunities; and ii) LX201, a
silicone matrix ocular (episcleral) implant that steadily releases
therapeutic doses of cyclosporine A locally to the eye. Both the
LUMINATE pivotal clinical program for LX211 for the treatment of uveitis,
as well as the LUCIDA pivotal clinical program with LX201 for the
prevention of corneal transplant rejection were initiated in early 2007.
-
Proprietary
product-enabling bio-erodible polymer technologies that facilitate
targeted and sustained delivery of molecules to the eye.
For more information on Lux Biosciences, please visit the
company’s website at
www.luxbio.com.
###
CONTACTS:
Lux Biosciences, Inc.
Ulrich Grau,
Ph.D.
+1 201 946 0221
Ulrich.grau@luxbio.com
Kureczka/Martin Associates (media)
Joan Kureczka
+1 415-821-2413
Jkureczka@comcast.net
© 2008 Lux
Biosciences, Inc. All rights reserved.
Web
Terms |
